{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:00:37Z","timestamp":1791450037482,"version":"4.3.3"},"reference-count":73,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000233","name":"Genome British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","award":["G05CHS"],"award-info":[{"award-number":["G05CHS"]}],"id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jval.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:13:37Z","timestamp":1691043217000},"page":"1608-1617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions"],"prefix":"10.1016","volume":"26","author":[{"given":"Deirdre","family":"Weymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Regier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.jval.2023.07.004_bib2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A\u00a0history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a000570","article-title":"Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers","volume":"1","author":"Laskin","year":"2015","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.07.004_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/cancers14071793","article-title":"Indirect treatment comparison of larotrectinib versus entrectinib in treating patients with TRK gene fusion cancers","volume":"14","author":"Garcia-Foncillas","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jval.2023.07.004_bib6","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.3389\/fmed.2021.818647","article-title":"Conditional drug approval as a path to market for oncology drugs in Canada: challenges and recommendations for assessing eligibility and regulatory responsiveness","volume":"8","author":"McPhail","year":"2022","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.jval.2023.07.004_bib7","first-page":"737","article-title":"FDA notches up third tissue-agnostic cancer approval","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jval.2023.07.004_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/curroncol29030156","article-title":"Is it time to commit to a process to re-evaluate oncology drugs? A descriptive analysis of systemic therapies for solid tumour indications reviewed in Canada from 2017 to 2021","volume":"29","author":"Sehdev","year":"2022","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.jval.2023.07.004_bib19","article-title":"Reimbursement Recommendation: Larotrectinib (Vitrakvi)","volume":"1","year":"2021","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.jval.2023.07.004_bib20","author":"Brogaard"},{"issue":"76","key":"10.1016\/j.jval.2023.07.004_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25760","article-title":"Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework","volume":"25","author":"Murphy","year":"2021","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40258-022-00740-1","article-title":"Economic evaluation of a tumour-agnostic therapy: Dutch economic value of larotrectinib in TRK fusion-positive cancers","volume":"20","author":"Michels","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jval.2022.08.006","article-title":"Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib","volume":"26","author":"Huygens","year":"2023","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2023.07.004_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jval.2022.01.005","article-title":"Defining a core data set for the economic evaluation of precision oncology","volume":"25","author":"Pollard","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib26","first-page":"467","article-title":"Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges","volume":"13","author":"Weymann","year":"2022","journal-title":"J\u00a0Community Genet"},{"issue":"9","key":"10.1016\/j.jval.2023.07.004_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jval.2018.06.017","article-title":"Methodological issues in assessing the economic value of next-generation sequencing tests: many\u00a0challenges and not enough solutions","volume":"21","author":"Phillips","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2023.07.004_bib28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jval.2018.06.010","article-title":"Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions","volume":"21","author":"Regier","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jval.2020.03.002","article-title":"Methods for moving the evaluation of precision medicine into practice and policy","volume":"23","author":"Phillips","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2023.07.004_bib30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/nhs.12048","article-title":"Content analysis and thematic analysis: implications for conducting a qualitative descriptive study","volume":"15","author":"Vaismoradi","year":"2013","journal-title":"Nurs Health Sci"},{"issue":"9","key":"10.1016\/j.jval.2023.07.004_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"10.1016\/j.jval.2023.07.004_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"7","key":"10.1016\/j.jval.2023.07.004_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jval.2023.07.004_bib34","doi-asserted-by":"crossref","first-page":"l6435","DOI":"10.1136\/bmj.l6435","article-title":"How should we assess the clinical and cost effectiveness of histology independent cancer drugs?","volume":"368","author":"Cooper","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0272989X20980327","article-title":"Exploring heterogeneity in histology-independent technologies and the implications for cost-effectiveness","volume":"41","author":"Murphy","year":"2021","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2023.07.004_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-020-00915-5","article-title":"Tumor-agnostic treatment for cancer: when how is better than where","volume":"40","author":"Lavacchi","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/cpt.1946","article-title":"Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine","volume":"109","author":"Seligson","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jval.2023.07.004_bib38","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1158\/1078-0432.CCR-18-3694","article-title":"Agnostic-histology approval of new drugs in oncology: are we already there? Are we ready for agnostic-histology approvals in oncology?","volume":"25","author":"Hierro","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jval.2023.07.004_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270571","article-title":"Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors","volume":"17","author":"Hibar","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40258-021-00654-4","article-title":"Developing a framework for the health technology assessment of histology-independent precision oncology therapies","volume":"19","author":"Gaultney","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2023.07.004_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jval.2016.10.014","article-title":"Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland","volume":"20","author":"Allen","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2023.07.004_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1468-0009.12476","article-title":"Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States","volume":"98","author":"Salcher-Konrad","year":"2020","journal-title":"Milbank Q"},{"key":"10.1016\/j.jval.2023.07.004_bib45","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jval.2020.08.399","article-title":"PCN262 understanding the challenges in the evaluation of tumour-agnostic therapies: barriers posed by the current trial designs and future trends","volume":"23","author":"Delimpaltadakis","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.07.004_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2019.02.013","article-title":"Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: a systematic literature review","volume":"137","author":"Branchoux","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jval.2023.07.004_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalmedicine"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2023.07.004_bib49","doi-asserted-by":"crossref","first-page":"viii713","DOI":"10.1093\/annonc\/mdy424.017","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.07.004_bib50","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jval.2023.07.004_bib51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2021.11.1354","article-title":"Comparison of alternative methods to assess the cost-effectiveness of tumor-agnostic therapies: a triangulation approach using larotrectinib as a case study","volume":"25","author":"Briggs","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.07.004_bib52","first-page":"S464","article-title":"PCN147 entrectinib in ntrk tumor agnostic indication compared to different standard of care in various tumors types: a cost-effectiveness analysis in Italian patients","volume":"22","author":"Bellone","year":"2019","journal-title":"Value Health"},{"issue":"9453","key":"10.1016\/j.jval.2023.07.004_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A\u00a0literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib55","first-page":"22","article-title":"Stakeholder perspectives on navigating evidentiary and decision uncertainty in precision oncology","volume":"12","author":"Pollard","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"4","key":"10.1016\/j.jval.2023.07.004_bib56","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib57","first-page":"296","article-title":"CADTH reimbursement review: entrectinib (Rozlytrek)","volume":"3","year":"2023","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.jval.2023.07.004_bib58","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/j.jval.2020.08.370","article-title":"PCN233 communicating value to payers for tumor-agnostic therapies","volume":"23","author":"Hunt","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.07.004_bib59","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1016\/j.jval.2020.08.222","article-title":"PCN85 an updated cost-utility analysis in Italian patients of entrectinib compared to standard of care in NTRK+ tumor agnostic indication","volume":"23","author":"Bellone","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2023.07.004_bib60","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/2159-8290.CD-21-0554","article-title":"Tissue-agnostic drug development: a new path to drug approval","volume":"11","author":"Thein","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib61","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jval.2021.11.714","article-title":"HM POSB. Bridging the evidence gap for tumor-agnostic therapies","volume":"25","author":"Coker","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20137","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1016\/j.jval.2023.07.004_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217559","article-title":"Developing a dynamic HIV transmission model for 6 US cities: an evidence synthesis","volume":"14","author":"Krebs","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2023.07.004_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non\u2013small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"10.1016\/j.jval.2023.07.004_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17547","article-title":"Correlation between surrogate end points and overall survival in a multi-institutional clinicogenomic cohort of patients with non\u2013small cell lung or colorectal cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2 suppl","key":"10.1016\/j.jval.2023.07.004_bib66","first-page":"S26","article-title":"Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer","volume":"28","author":"Carlson","year":"2022","journal-title":"Am J Manag Care"},{"issue":"14","key":"10.1016\/j.jval.2023.07.004_bib67","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/cer-2021-0247","article-title":"Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers","volume":"11","author":"Suh","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"6","key":"10.1016\/j.jval.2023.07.004_bib68","first-page":"622","article-title":"The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma","volume":"28","author":"Suh","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jval.2023.07.004_bib71","series-title":"Challenges estimating the economic value of tissue-agnostic anti-cancer treatments","author":"Sullivan","year":"2018"},{"key":"10.1016\/j.jval.2023.07.004_bib72","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jval.2023.07.004_bib73","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/pds.4196","article-title":"Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013","volume":"26","author":"Bouvy","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.jval.2023.07.004_bib74","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jval.2023.01.011","article-title":"Challenges and solutions for the benefit assessment of tumor-agnostic therapies in Germany","volume":"26","author":"Schiller","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib75","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1002\/mgg3.1554","article-title":"Matching methods in precision oncology: an introduction and illustrative example","volume":"9","author":"Weymann","year":"2021","journal-title":"Mol Genet Genom Med"},{"issue":"12","key":"10.1016\/j.jval.2023.07.004_bib76","first-page":"86","article-title":"Developing data sharing models for Health Research with real-world data: a scoping review of patient and public preferences","volume":"46","author":"Hermansen","year":"2022","journal-title":"J\u00a0Med Syst"},{"issue":"1","key":"10.1016\/j.jval.2023.07.004_bib77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41698-022-00316-1","article-title":"A\u00a0perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada","volume":"6","author":"Regier","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"3","key":"10.1016\/j.jval.2023.07.004_bib78","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2023.07.004_bib79","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions","volume":"15","author":"Walker","year":"2012","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","article-title":"Access with evidence development schemes","volume":"28","author":"McCabe","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11530860-000000000-00000","article-title":"signatories to the Consensus Statement. Principles of design of access with evidence development approaches","volume":"28","author":"Menon","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2023.07.004_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40273-012-0013-6","article-title":"When does NICE recommend the use of health technologies within a programme of evidence development?","volume":"31","author":"Longworth","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"46","key":"10.1016\/j.jval.2023.07.004_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16460","article-title":"Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development","volume":"16","author":"Claxton","year":"2012","journal-title":"Health Technol Assess"},{"issue":"6","key":"10.1016\/j.jval.2023.07.004_bib84","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jval.2016.03.2003","article-title":"A\u00a0comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions","volume":"19","author":"Claxton","year":"2016","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2023.07.004_bib85","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","article-title":"Performance-based risk-sharing arrangements: an updated international review","volume":"35","author":"Carlson","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2023.07.004_bib86","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jval.2018.11.010","article-title":"Uncertainty and coverage with evidence development: does practice meet theory?","volume":"22","author":"Pouwels","year":"2019","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2023.07.004_bib87","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jval.2014.01.010","article-title":"Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement\u00a0strategy for innovative technologies?","volume":"17","author":"Edlin","year":"2014","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152303070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152303070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:33:18Z","timestamp":1761096798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152303070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S109830152303070X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.07.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}